



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

23 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	New	Total
1 st dose	130,615	2,035,549
2 nd dose	18,528	79,151

※ Figures based on recorded data and subject to correction

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,114,700	279	0.62%	275	1	2	1
	Total		13,011		12,787	132	39	53
AstraZeneca	New	1,194,726	209	0.98%	208	1	0	0
	Total		11,685		11,510	110	28	37
Pfizer	New	919,974	70	0.14%	67	0	2	1
	Total		1,326		1,277	22	11	16


¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases





KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

23 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		797 (100)	117,458 (100)	226.55
Sex	Male	393 (49.31)	58,438 (49.75)	225.95
	Female	404 (50.69)	59,020 (50.25)	227.13
Age	80 or above	55 (6.90)	5,188 (4.42)	273.16
	70-79	56 (7.03)	8,529 (7.26)	236.45
	60-69	94 (11.79)	18,097 (15.41)	285.25
	50-59	141 (17.69)	21,766 (18.53)	251.14
	40-49	119 (14.93)	17,372 (14.79)	207.07
	30-39	112 (14.05)	15,796 (13.45)	224.21
	20-29	112 (14.05)	17,454 (14.86)	256.43
	0-9	53 (6.65)	5,064 (4.31)	122.06

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		3 (100)	1,811 (100)	1.54	127 (100.0)
Sex	Male	2 (66.67)	902 (49.81)	1.54	83 (65.4)
	Female	1 (33.33)	909 (50.19)	1.54	44 (34.6)
Age	80 or above	2 (66.67)	994 (54.89)	19.16	35 (27.6)
	70-79	0 (0.00)	519 (28.66)	6.09	39 (30.7)
	60-69	0 (0.00)	212 (11.71)	1.17	35 (27.6)
	50-59	1 (33.33)	62 (3.42)	0.28	13 (10.2)
	40-49	0 (0.00)	14 (0.77)	0.08	4 (3.1)
	30-39	0 (0.00)	7 (0.39)	0.04	0 (0.0)
	20-29	0 (0.00)	3 (0.17)	0.02	1 (0.8)
	0-9	0 (0.00)	0 (0.00)	0.00	0 (0.0)

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.10.	4.11.	4.12.	4.13.	4.14.	4.15.	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.
Total	108	105	103	101	100	99	111	108	102	99	109	116	125	127

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)